JP2024527879A5 - - Google Patents

Info

Publication number
JP2024527879A5
JP2024527879A5 JP2024503984A JP2024503984A JP2024527879A5 JP 2024527879 A5 JP2024527879 A5 JP 2024527879A5 JP 2024503984 A JP2024503984 A JP 2024503984A JP 2024503984 A JP2024503984 A JP 2024503984A JP 2024527879 A5 JP2024527879 A5 JP 2024527879A5
Authority
JP
Japan
Prior art keywords
composition according
chain
sequence
sequence number
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527879A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/074062 external-priority patent/WO2023004425A2/en
Publication of JP2024527879A publication Critical patent/JP2024527879A/ja
Publication of JP2024527879A5 publication Critical patent/JP2024527879A5/ja
Pending legal-status Critical Current

Links

JP2024503984A 2021-07-23 2022-07-22 養子免疫療法のための機能が強化されたｃｄ３発現ナチュラルキラー細胞 Pending JP2024527879A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163225281P 2021-07-23 2021-07-23
US63/225,281 2021-07-23
US202263310526P 2022-02-15 2022-02-15
US63/310,526 2022-02-15
US202263344931P 2022-05-23 2022-05-23
US63/344,931 2022-05-23
PCT/US2022/074062 WO2023004425A2 (en) 2021-07-23 2022-07-22 Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy

Publications (2)

Publication Number Publication Date
JP2024527879A JP2024527879A (ja) 2024-07-26
JP2024527879A5 true JP2024527879A5 (enExample) 2025-07-29

Family

ID=84978775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503984A Pending JP2024527879A (ja) 2021-07-23 2022-07-22 養子免疫療法のための機能が強化されたｃｄ３発現ナチュラルキラー細胞

Country Status (9)

Country Link
US (1) US20240325443A1 (enExample)
EP (1) EP4373501A4 (enExample)
JP (1) JP2024527879A (enExample)
KR (1) KR20240041964A (enExample)
AU (1) AU2022315301A1 (enExample)
CA (1) CA3227317A1 (enExample)
IL (1) IL310307A (enExample)
MX (1) MX2024001073A (enExample)
WO (1) WO2023004425A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
KR20250166262A (ko) * 2023-03-24 2025-11-27 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 향상된 항종양 기억 반응을 갖는 조작된 자연 살해 세포
WO2024232948A1 (en) * 2023-05-05 2024-11-14 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
WO2026077446A1 (en) * 2024-10-12 2026-04-16 Nanjing Legend Biotech Co., Ltd. Engineered il-15 constructs and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010580B1 (pt) * 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
WO2016054520A2 (en) * 2014-10-03 2016-04-07 The California Institute For Biomedical Research Engineered cell surface proteins and uses thereof
US11667691B2 (en) * 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
WO2017192536A1 (en) * 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
WO2018129199A1 (en) * 2017-01-04 2018-07-12 Nova Southeastern University Natural killer (nk) cells expressing an antigen-specific functional t cell receptor (tcr) complex, methods for production thereof, and methods for therapeutic use thereof
CA3077352A1 (en) * 2017-10-05 2019-04-11 Nantcell, Inc. Lipid-based antigens and t-cell receptors on nk cells
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
MX2021011816A (es) * 2019-03-29 2021-10-22 Univ Texas Metodos para produccion de celulas car-nk y uso de las mismas.
EP3750547A1 (en) * 2019-06-13 2020-12-16 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Modified nk-92 cells, and therapeutic and diagnostic uses thereof
KR20220038399A (ko) * 2019-07-23 2022-03-28 웬 양 차용 면역치료법을 위한 조성물 및 방법

Similar Documents

Publication Publication Date Title
JP2024527879A5 (enExample)
US11679132B2 (en) Methods for enhancing efficacy of therapeutic immune cells
JP2022066290A5 (enExample)
JP2022541441A5 (enExample)
JP2021519061A5 (enExample)
JP2022510207A5 (enExample)
AU2017301880A1 (en) Immunomodulatory polypeptides and related compositions and methods
JP2018532432A5 (enExample)
JP2024023228A5 (enExample)
AU2018313952A1 (en) Methods and compositions for preparing genetically engineered cells
AU2023206126B2 (en) TGF-β receptors and methods of use
JP2017515464A5 (enExample)
JP2024513906A5 (enExample)
EP3098237A1 (en) Anti-toso chimeric antigen receptor and its use
JP2022548902A5 (enExample)
JP2023545992A5 (enExample)
JP2024515920A5 (enExample)
JP2023515055A5 (enExample)
JP2025527657A5 (enExample)
US20220118014A1 (en) Placenta-derived allogeneic car-t cells and uses thereof
JP2024526237A5 (enExample)
HK40086170A (en) Methods for enhancing efficacy of therapeutic immune cells
KR20220110199A (ko) 태반-유래 동종이계 car-t 세포 및 이의 용도
RU2021116146A (ru) Nk-клетки с химерным антигенным рецептором, подобные клеткам памяти (carml), и способы их получения и примения
WO2025130895A1 (zh) 一种免疫细胞的制备方法及其用途